Top

Current Heart Failure Reports

Published in:

01-10-2019 | Sarcopenia | Biomarkers of Heart Failure (J. Grodin & W.H.W. Tang, Section Editors)

Anabolism to Catabolism: Serologic Clues to Nutritional Status in Heart Failure

Authors: Laura Murphy, Alastair Gray, Emer Joyce

Published in: Current Heart Failure Reports | Issue 5/2019

Abstract

Purpose of Review

Malnutrition, sarcopenia, and cachexia are areas of increasing interest in the management of patients with heart failure (HF). This review aims to examine the serological markers useful in guiding the physician in identification of these patients.

Recent Findings

Traditional nutritional biomarkers including albumin/prealbumin, iron, and vitamin D deficiencies predict poor prognosis in malnutrition and HF. Novel biomarkers including ghrelin, myostatin, C-terminal agrin fragment, and adiponectin have been identified as possible substrates and/or therapeutic targets in cardiac patients with sarcopenia and cachexia, though clinical trial data is limited to date.

Summary

Increased focus on nutritional deficiency syndromes in heart failure has led to the use of established markers of malnutrition as well as the identification of novel biomarkers in the management of these patients, though to date, their usage has been confined to the academic domain and further research is required to establish their role in the clinical setting.

Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke Statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603. https://doi.org/10.1161/cir.0000000000000485.CrossRefPubMedPubMedCentral

Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606–19. https://doi.org/10.1161/HHF.0b013e318291329a.CrossRefPubMedPubMedCentral

Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18(6):613–25. https://doi.org/10.1002/ejhf.566.CrossRefPubMed

Raposo André T, Lopes-Santos A. I GN. Cardiac Cachexia syndrome. Eur Med J Cardiol. 2017;5(1):101–7.

Goyal P, Almarzooq ZI, Horn EM, Karas MG, Sobol I, Swaminathan RV, et al. Characteristics of Hospitalizations for Heart Failure with Preserved Ejection Fraction. Am J Med. 2016;129(6):635.e15–26. https://doi.org/10.1016/j.amjmed.2016.02.007.CrossRef

McNallan SM, Chamberlain AM, Gerber Y, Singh M, Kane RL, Weston SA, et al. Measuring frailty in heart failure: a community perspective. Am Heart J. 2013;166(4):768–74. https://doi.org/10.1016/j.ahj.2013.07.008.CrossRefPubMed

Vidan MT, Sanchez E, Fernandez-Aviles F, Serra-Rexach JA, Ortiz J, Bueno H. FRAIL-HF, a study to evaluate the clinical complexity of heart failure in nondependent older patients: rationale, methods and baseline characteristics. Clin Cardiol. 2014;37(12):725–32. https://doi.org/10.1002/clc.22345.CrossRefPubMedPubMedCentral

Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–56. https://doi.org/10.1093/gerona/56.3.m146.CrossRefPubMed

Cederholm T, Bosaeus I, Barazzoni R, Bauer J, Van Gossum A, Klek S, et al. Diagnostic criteria for malnutrition - An ESPEN Consensus Statement. Clin Nutr (Edinburgh, Scotland). 2015;34(3):335–40. https://doi.org/10.1016/j.clnu.2015.03.001.CrossRef

10.

Tevik K, Thurmer H, Husby MI, de Soysa AK, Helvik AS. Nutritional risk screening in hospitalized patients with heart failure. Clin Nutr (Edinburgh, Scotland). 2015;34(2):257–64. https://doi.org/10.1016/j.clnu.2014.03.014.CrossRef

11.

Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J. 2015;36(11):657–68. https://doi.org/10.1093/eurheartj/ehu385.CrossRefPubMed

12.

Lin H, Zhang H, Lin Z, Li X, Kong X, Sun G. Review of nutritional screening and assessment tools and clinical outcomes in heart failure. Heart Fail Rev. 2016;21(5):549–65. https://doi.org/10.1007/s10741-016-9540-0.CrossRefPubMed

13.

Kruizenga HM, Seidell JC, de Vet HC, Wierdsma NJ, van Bokhorst-de van der Schueren MA. Development and validation of a hospital screening tool for malnutrition: the short nutritional assessment questionnaire (SNAQ). Clin Nutr (Edinburgh, Scotland). 2005;24(1):75–82. https://doi.org/10.1016/j.clnu.2004.07.015.CrossRef

14.

Hajahmadi M, Shemshadi S, Khalilipur E, Amin A, Taghavi S, Maleki M, et al. Muscle wasting in young patients with dilated cardiomyopathy. J Cachexia Sarcopenia Muscle. 2017;8(4):542–8. https://doi.org/10.1002/jcsm.12193.CrossRefPubMedPubMedCentral

15.

• Iwakami N, Nagai T, Furukawa TA, Sugano Y, Honda S, Okada A, et al. Prognostic value of malnutrition assessed by controlling nutritional status score for long-term mortality in patients with acute heart failure. Int J Cardiol. 2017;230:529–36. https://doi.org/10.1016/j.ijcard.2016.12.064 This study highlights the importance of assessing nutritional status in acute HF patients due to the significant association with increased mortality identified in this group. CrossRefPubMed

16.

Sargento L, Satendra M, Almeida I, Sousa C, Gomes S, Salazar F, et al. Nutritional status of geriatric outpatients with systolic heart failure and its prognostic value regarding death or hospitalization, biomarkers and quality of life. J Nutr Health Aging. 2013;17(4):300–4. https://doi.org/10.1007/s12603-013-0030-y.CrossRefPubMed

17.

• Lewis GD, Malhotra R, Hernandez AF, SE MN, Smith A, Felker GM, et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical TrialOral Iron for Heart FailureOral Iron for Heart Failure. JAMA. 2017;317(19):1958–66. https://doi.org/10.1001/jama.2017.5427 The results for IV iron have previously been promising with improvements in exercise capacity in HF patients however, this study examines the use of oral iron and found it to be of little benefit in the treatment group. CrossRefPubMedPubMedCentral

18.

Chiarantini D, Volpato S, Sioulis F, Bartalucci F, Del Bianco L, Mangani I, et al. Lower extremity performance measures predict long-term prognosis in older patients hospitalized for heart failure. J Card Fail. 2010;16(5):390–5. https://doi.org/10.1016/j.cardfail.2010.01.004.CrossRefPubMed

19.

Chung CJ, Wu C, Jones M, Kato TS, Dam TT, Givens RC, et al. Reduced handgrip strength as a marker of frailty predicts clinical outcomes in patients with heart failure undergoing ventricular assist device placement. J Card Fail. 2014;20(5):310–5. https://doi.org/10.1016/j.cardfail.2014.02.008.CrossRefPubMedPubMedCentral

20.

Adejumo OL, Koelling TM, Hummel SL. Nutritional risk index predicts mortality in hospitalized advanced heart failure patients. J Heart Lung Transplant : the official publication of the International Society for Heart Transplantation. 2015;34(11):1385–9. https://doi.org/10.1016/j.healun.2015.05.027.CrossRef

21.

Santilli V, Bernetti A, Mangone M, Paoloni M. Clinical definition of sarcopenia. Clin Cases Mineral Bone Metab : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases. 2014;11(3):177–80.

22.

Fulster S, Tacke M, Sandek A, Ebner N, Tschope C, Doehner W, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2013;34(7):512–9. https://doi.org/10.1093/eurheartj/ehs381.CrossRefPubMed

23.

Yost G, Bhat G. Relationship between handgrip strength and length of stay for left ventricular assist device implantation. Nutr Clin Pract : official publication of the American Society for Parenteral and Enteral Nutrition. 2017;32(1):98–102. https://doi.org/10.1177/0884533616665926.CrossRef

24.

Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol. 2002;85(1):51–66.CrossRefPubMed

25.

Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr (Edinburgh, Scotland). 2008;27(6):793–9. https://doi.org/10.1016/j.clnu.2008.06.013.CrossRef

26.

Farkas J, von Haehling S, Kalantar-Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle. 2013;4(3):173–8. https://doi.org/10.1007/s13539-013-0105-y.CrossRefPubMedPubMedCentral

27.

Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet (London, England). 1997;349(9058):1050–3. https://doi.org/10.1016/s0140-6736(96)07015-8.CrossRef

28.

Kondrup J, Rasmussen HH, Hamberg O, Stanga Z. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr (Edinburgh, Scotland). 2003;22(3):321–36.CrossRef

29.

Heberton GA, Nassif M, Bierhals A, Novak E, LaRue SJ, Lima B, et al. Usefulness of psoas muscle area determined by computed tomography to predict mortality or prolonged length of hospital stay in patients undergoing left ventricular assist device implantation. Am J Cardiol. 2016;118(9):1363–7. https://doi.org/10.1016/j.amjcard.2016.07.061.CrossRefPubMed

30.

Bibas L, Saleh E, Alkharji S, Chetrit J, Mullie L, Cantarovich M, et al. Sarcopenia and mortality after heart transplantation. Can J Cardiol. 2017;33(10):S71–S2. https://doi.org/10.1016/j.cjca.2017.07.145.CrossRef

31.

Kumar A, Ansari BA, Kim J, Suri A, Gaddam S, Yenigalla S, et al. Axial muscle size as a strong predictor of death in subjects with and without heart failure. J Am Heart Assoc. 2019;8(4):e010554. https://doi.org/10.1161/jaha.118.010554.CrossRefPubMedPubMedCentral

32.

Rossignol P, Masson S, Barlera S, Girerd N, Castelnovo A, Zannad F, et al. Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. Eur J Heart Fail. 2015;17(4):424–33. https://doi.org/10.1002/ejhf.240.CrossRefPubMed

33.

Tsuchida K, Fujihara Y, Hiroki J, Hakamata T, Sakai R, Nishida K, et al. Significance of Sarcopenia Evaluation in Acute Decompensated Heart Failure. Skeletal Muscle Mass Index versus Fat-Free Mass Index. Int Heart J. 2018;59(1):143–8. https://doi.org/10.1536/ihj.17-057.CrossRefPubMed

34.

Narumi T, Watanabe T, Kadowaki S, Takahashi T, Yokoyama M, Kinoshita D, et al. Sarcopenia evaluated by fat-free mass index is an important prognostic factor in patients with chronic heart failure. Eur J Int Med. 2015;26(2):118–22. https://doi.org/10.1016/j.ejim.2015.01.008.CrossRef

35.

Melenovsky V, Kotrc M, Borlaug BA, Marek T, Kovar J, Malek I, et al. Relationships between right ventricular function, body composition, and prognosis in advanced heart failure. J Am Coll Cardiol. 2013;62(18):1660–70. https://doi.org/10.1016/j.jacc.2013.06.046.CrossRefPubMed

36.

Kuzuya M, Izawa S, Enoki H, Okada K, Iguchi A. Is serum albumin a good marker for malnutrition in the physically impaired elderly? Clin Nutr (Edinburgh, Scotland). 2007;26(1):84–90. https://doi.org/10.1016/j.clnu.2006.07.009.CrossRef

37.

Bharadwaj S, Ginoya S, Tandon P, Gohel TD, Guirguis J, Vallabh H, et al. Malnutrition: laboratory markers vs nutritional assessment. Gastroenterol Rep (Oxf). 2016;4(4):272–80. https://doi.org/10.1093/gastro/gow013.CrossRef

38.

Lourenço P, Silva S, Friões F, Alvelos M, Amorim M, Couto M, et al. Low prealbumin is strongly associated with adverse outcome in heart failure. Heart. 2014;100(22):1780–5. https://doi.org/10.1136/heartjnl-2014-305747.CrossRefPubMed

39.

von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron deficiency in heart failure: an overview. JACC Heart failure. 2019;7(1):36–46. https://doi.org/10.1016/j.jchf.2018.07.015.CrossRef

40.

Cappellini MD, Comin-Colet J, de Francisco A, Dignass A, Doehner W, Lam CS, et al. Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management. Am J Hematol. 2017;92(10):1068–78. https://doi.org/10.1002/ajh.24820.CrossRefPubMedPubMedCentral

41.

Boulton FE. The myoglobin content of human skeletal muscle. Br J Haematol. 1973;25(2):281.PubMed

42.

Stugiewicz M, Tkaczyszyn M, Kasztura M, Banasiak W, Ponikowski P, Jankowska EA. The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications. Eur J Heart Fail. 2016;18(7):762–73. https://doi.org/10.1002/ejhf.467.CrossRefPubMed

43.

Martens P, Nijst P, Verbrugge FH, Smeets K, Dupont M, Mullens W. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. Acta Cardiol. 2018;73(2):115–23. https://doi.org/10.1080/00015385.2017.1351239.CrossRefPubMed

44.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30. https://doi.org/10.1210/jc.2011-0385.CrossRefPubMed

45.

Witte KK, Byrom R, Gierula J, Paton MF, Jamil HA, Lowry JE, et al. Effects of vitamin D on cardiac function in patients with chronic HF: the VINDICATE study. J Am Coll Cardiol. 2016;67(22):2593–603. https://doi.org/10.1016/j.jacc.2016.03.508.CrossRefPubMedPubMedCentral

46.

Sanders KM, Scott D, Ebeling PR. Vitamin D deficiency and its role in muscle-bone interactions in the elderly. Curr Osteoporos Rep. 2014;12(1):74–81. https://doi.org/10.1007/s11914-014-0193-4.CrossRefPubMed

47.

Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the longitudinal aging study Amsterdam. J Clin Endocrinol Metab. 2003;88(12):5766–72. https://doi.org/10.1210/jc.2003-030604.CrossRefPubMed

48.

Wicherts IS, van Schoor NM, Boeke AJ, Visser M, Deeg DJ, Smit J, et al. Vitamin D status predicts physical performance and its decline in older persons. J Clin Endocrinol Metab. 2007;92(6):2058–65. https://doi.org/10.1210/jc.2006-1525.CrossRefPubMed

49.

Costanzo S, De Curtis A, Di Castelnuovo A, Persichillo M, Bonaccio M, Pounis G, et al. Serum vitamin D deficiency and risk of hospitalization for heart failure: prospective results from the Moli-sani study. Nutr Metab Cardiovasc Dis : NMCD. 2018;28(3):298–307. https://doi.org/10.1016/j.numecd.2017.11.008.CrossRefPubMed

50.

Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13(6):422–30. https://doi.org/10.1016/j.cardfail.2007.03.011.CrossRefPubMed

51.

Tuegel C, Bansal N. Heart failure in patients with kidney disease. Heart. 2017;103(23):1848–53. https://doi.org/10.1136/heartjnl-2016-310794.CrossRefPubMed

52.

Shlipak MG, Stehman-Breen C, Fried LF, Song X, Siscovick D, Fried LP, et al. The presence of frailty in elderly persons with chronic renal insufficiency. Am J Kidney Dis : the official journal of the National Kidney Foundation. 2004;43(5):861–7.CrossRef

53.

Maurer MS, Horn E, Reyentovich A, Dickson VV, Pinney S, Goldwater D, et al. Can a left ventricular assist device in individuals with advanced systolic heart failure improve or reverse frailty? J Am Geriatr Soc. 2017;65(11):2383–90. https://doi.org/10.1111/jgs.15124.CrossRefPubMedPubMedCentral

54.

Jenkins R, Mandarano L, Gugathas S, Kaski JC, Anderson L, Banerjee D. Impaired renal function affects clinical outcomes and management of patients with heart failure. ESC heart failure. 2017;4(4):576–84. https://doi.org/10.1002/ehf2.12185.CrossRefPubMedPubMedCentral

55.

KDOQI. Clinical practice guidelines and clinical practice recommendations for Anemia in chronic kidney disease. Am J Kidney Dis : the official journal of the National Kidney Foundation. 2006;47(5 Suppl 3):S11–145. https://doi.org/10.1053/j.ajkd.2006.03.010.CrossRef

56.

Zhou Y, Hellberg M, Svensson P, Hoglund P, Clyne N. Sarcopenia and relationships between muscle mass, measured glomerular filtration rate and physical function in patients with chronic kidney disease stages 3-5. Nephrol Dialysis Transplant : official publication of the European Dialysis and Transplant Association - European Renal Association. 2018;33(2):342–8. https://doi.org/10.1093/ndt/gfw466.CrossRef

57.

Pereira RA, Cordeiro AC, Avesani CM, Carrero JJ, Lindholm B, Amparo FC, et al. Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality. Nephrol Dialysis Transplant : official publication of the European Dialysis and Transplant Association - European Renal Association. 2015;30(10):1718–25. https://doi.org/10.1093/ndt/gfv133.CrossRef

58.

Anker SD, Ponikowski PP, Clark AL, Leyva F, Rauchhaus M, Kemp M, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 1999;20(9):683–93. https://doi.org/10.1053/euhj.1998.1446.CrossRefPubMed

59.

Cesari M, Penninx BW, Pahor M, Lauretani F, Corsi AM, Rhys Williams G, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59(3):242–8. https://doi.org/10.1093/gerona/59.3.m242.CrossRefPubMed

60.

Bian AL, Hu HY, Rong YD, Wang J, Wang JX, Zhou XZ. A study on relationship between elderly sarcopenia and inflammatory factors IL-6 and TNF-alpha. Eur J Med Res. 2017;22(1):25. https://doi.org/10.1186/s40001-017-0266-9.CrossRefPubMedPubMedCentral

61.

Yoshihisa A, Kanno Y, Watanabe S, Yokokawa T, Abe S, Miyata M, et al. Impact of nutritional indices on mortality in patients with heart failure. Open heart. 2018;5(1):e000730. https://doi.org/10.1136/openhrt-2017-000730.CrossRefPubMedPubMedCentral

62.

Castellano G, Affuso F, Conza PD, Fazio S. The GH/IGF-1 Axis and heart failure. Curr Cardiol Rev. 2009;5(3):203–15. https://doi.org/10.2174/157340309788970306.CrossRefPubMedPubMedCentral

63.

Anker SD, Volterrani M, Pflaum CD, Strasburger CJ, Osterziel KJ, Doehner W, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol. 2001;38(2):443–52.CrossRefPubMed

64.

Cittadini A, Saldamarco L, Marra AM, Arcopinto M, Carlomagno G, Imbriaco M, et al. Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. J Clin Endocrinol Metab. 2009;94(9):3329–36. https://doi.org/10.1210/jc.2009-0533.CrossRefPubMed

65.

Bhandari SS, Narayan H, Jones DJ, Suzuki T, Struck J, Bergmann A, et al. Plasma growth hormone is a strong predictor of risk at 1 year in acute heart failure. Eur J Heart Fail. 2016;18(3):281–9. https://doi.org/10.1002/ejhf.459.CrossRefPubMed

66.

Hassfeld S, Eichhorn C, Stehr K, Naegele H, Geier C, Steeg M, et al. Insulin-like growth factor-binding proteins 2 and 3 are independent predictors of a poor prognosis in patients with dilated cardiomyopathy. Heart. 2007;93(3):359–60. https://doi.org/10.1136/hrt.2006.090092.CrossRefPubMedPubMedCentral

67.

Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104–15.CrossRefPubMed

68.

Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med. 2013;10(1):245–84. https://doi.org/10.1111/j.1743-6109.2012.02783.x.CrossRefPubMed

69.

Kalicinska E, Wojtas K, Majda J, Doehner W, von Haehling S, Banasiak W, et al. Anabolic deficiencies in men with systolic heart failure: do co-morbidities and therapies really contribute significantly? Aging Male : the official journal of the International Society for the Study of the Aging Male. 2013;16(3):123–31. https://doi.org/10.3109/13685538.2013.807427.CrossRef

70.

Wu HY, Wang XF, Wang JH, Li JY. Testosterone level and mortality in elderly men with systolic chronic heart failure. Asian J Androl. 2011;13(5):759–63. https://doi.org/10.1038/aja.2011.26.CrossRefPubMedPubMedCentral

71.

Jankowska EA, Filippatos G, Ponikowska B, Borodulin-Nadzieja L, Anker SD, Banasiak W, et al. Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J Card Fail. 2009;15(5):442–50. https://doi.org/10.1016/j.cardfail.2008.12.011.CrossRefPubMed

72.

Jankowska EA, Biel B, Ponikowska B, Borodulin-Nadzieja L, Petruk-Kowalczyk J, Banasiak W, et al. 679 Reduction in serum testosterone deteriorates exercise capacity in men in the course of chronic heart failure. Eur J Heart Fail Suppl. 2007;6(S1):148. https://doi.org/10.1016/S1567-4215(07)60413-5.CrossRef

73.

Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006;114(17):1829–37. https://doi.org/10.1161/circulationaha.106.649426.CrossRefPubMed

74.

Loncar G, Springer J, Anker M, Doehner W, Lainscak M. Cardiac cachexia: hic et nunc. J Cachexia Sarcopenia Muscle. 2016;7(3):246–60. https://doi.org/10.1002/jcsm.12118.CrossRefPubMedPubMedCentral

75.

Serra-Prat M, Palomera E, Roca M, Puig-Domingo M. Long-term effect of ghrelin on nutritional status and functional capacity in the elderly: a population-based cohort study. Clin Endocrinol. 2010;73(1):41–7. https://doi.org/10.1111/j.1365-2265.2009.03730.x.CrossRef

76.

Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M, Okumura H, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation. 2001;104(17):2034–8.CrossRefPubMed

77.

Steinbeck L, Ebner N, Valentova M, Bekfani T, Elsner S, Dahinden P, et al. Detection of muscle wasting in patients with chronic heart failure using C-terminal agrin fragment: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur J Heart Fail. 2015;17(12):1283–93. https://doi.org/10.1002/ejhf.400.CrossRefPubMed

78.

Araujo JP, Lourenco P, Rocha-Goncalves F, Ferreira A, Bettencourt P. Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Heart Fail. 2009;11(6):567–72. https://doi.org/10.1093/eurjhf/hfp046.CrossRefPubMed

79.

Szabo T, Scherbakov N, Sandek A, Kung T, von Haehling S, Lainscak M, et al. Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr Metab Cardiovasc Dis : NMCD. 2014;24(1):50–6. https://doi.org/10.1016/j.numecd.2013.04.015.CrossRefPubMed

80.

Breitbart A, Auger-Messier M, Molkentin JD, Heineke J. Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am J Physiol Heart Circ Physiol. 2011;300(6):H1973–H82. https://doi.org/10.1152/ajpheart.00200.2011.CrossRefPubMedPubMedCentral

81.

Lenk K, Schur R, Linke A, Erbs S, Matsumoto Y, Adams V, et al. Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur J Heart Fail. 2009;11(4):342–8. https://doi.org/10.1093/eurjhf/hfp020.CrossRefPubMed

82.

• Vest AR, Chan M, Deswal A, Givertz MM, Lekavich C, Lennie T, et al. Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee. J Card Fail. 2019;25(5):380–400. https://doi.org/10.1016/j.cardfail.2019.03.007 This article suggests an approach to the assessment of HF patients (both inpatients and outpatients) with malnutrition in combination with either cachexia and obesity and a management strategy for each cohort. CrossRefPubMed

83.

Rozentryt P, von Haehling S, Lainscak M, Nowak JU, Kalantar-Zadeh K, Polonski L, et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachexia Sarcopenia Muscle. 2010;1(1):35–42. https://doi.org/10.1007/s13539-010-0008-0.CrossRefPubMedPubMedCentral

84.

Aquilani R, Viglio S, Iadarola P, Opasich C, Testa A, Dioguardi FS, et al. Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure. Am J Cardiol. 2008;101(11a):104e–10e. https://doi.org/10.1016/j.amjcard.2008.03.008.CrossRefPubMed

85.

Forbes SC, Little JP, Candow DG. Exercise and nutritional interventions for improving aging muscle health. Endocrine. 2012;42(1):29–38. https://doi.org/10.1007/s12020-012-9676-1.CrossRefPubMed

86.

Gould DW, Lahart I, Carmichael AR, Koutedakis Y, Metsios GS. Cancer cachexia prevention via physical exercise: molecular mechanisms. J Cachexia Sarcopenia Muscle. 2013;4(2):111–24. https://doi.org/10.1007/s13539-012-0096-0.CrossRefPubMed

87.

Lenk K, Erbs S, Hollriegel R, Beck E, Linke A, Gielen S, et al. Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure. Eur J Prev Cardiol. 2012;19(3):404–11. https://doi.org/10.1177/1741826711402735.CrossRefPubMed

88.

Clark AL, Coats AJS, Krum H, Katus HA, Mohacsi P, Salekin D, et al. Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. J Cachexia Sarcopenia Muscle. 2017;8(4):549–56. https://doi.org/10.1002/jcsm.12191.CrossRefPubMedPubMedCentral

89.

Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet (London, England). 2003;361(9363):1077–83. https://doi.org/10.1016/s0140-6736(03)12892-9.CrossRef

90.

Khawaja T, Chokshi A, Ji R, Kato TS, Xu K, Zizola C, et al. Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone/insulin-like growth factor-1 axis signaling in patients with advanced heart failure. J Cachexia Sarcopenia Muscle. 2014;5(4):297–305. https://doi.org/10.1007/s13539-014-0155-9.CrossRefPubMedPubMedCentral

91.

Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436–48. https://doi.org/10.1056/NEJMoa0908355.CrossRefPubMed

92.

Bauer JM, Verlaan S, Bautmans I, Brandt K, Donini LM, Maggio M, et al. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: a randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc. 2015;16(9):740–7. https://doi.org/10.1016/j.jamda.2015.05.021.CrossRefPubMed

93.

Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107(25):3133–40. https://doi.org/10.1161/01.Cir.0000077913.60364.D2.CrossRefPubMed

94.

Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized Etanercept worldwide evaluation (RENEWAL). Circulation. 2004;109(13):1594–602. https://doi.org/10.1161/01.Cir.0000124490.27666.B2.CrossRefPubMed

95.

Everett Brendan M, Cornel Jan H, Lainscak M, Anker Stefan D, Abbate A, Thuren T, et al. Anti-inflammatory therapy with Canakinumab for the prevention of hospitalization for heart failure. Circulation. 2019;139(10):1289–99. https://doi.org/10.1161/CIRCULATIONAHA.118.038010.CrossRefPubMed

96.

Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009;54(10):919–27. https://doi.org/10.1016/j.jacc.2009.04.078.CrossRefPubMed

97.

Iellamo F, Volterrani M, Caminiti G, Karam R, Massaro R, Fini M, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol. 2010;56(16):1310–6. https://doi.org/10.1016/j.jacc.2010.03.090.CrossRefPubMed

98.

Stout M, Tew GA, Doll H, Zwierska I, Woodroofe N, Channer KS, et al. Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study. Am Heart J. 2012;164(6):893–901. https://doi.org/10.1016/j.ahj.2012.09.016.CrossRefPubMed

99.

Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335–45. https://doi.org/10.1016/s1470-2045(13)70055-x.CrossRefPubMedPubMedCentral

100.

Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation. 2004;110(24):3674–9. https://doi.org/10.1161/01.Cir.0000149746.62908.Bb.CrossRefPubMed

101.

Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 2018;124(3):606–16. https://doi.org/10.1002/cncr.31128.CrossRefPubMed

102.

Ebner N, von Haehling S. Unlocking the wasting enigma: highlights from the 8th Cachexia conference. J Cachexia Sarcopenia Muscle. 2016;7(1):90–4. https://doi.org/10.1002/jcsm.12106.CrossRefPubMedPubMedCentral

103.

Polkey MI, Praestgaard J, Berwick A, Franssen FME, Singh D, Steiner MC, et al. Activin type II receptor blockade for treatment of muscle depletion in chronic obstructive pulmonary disease. A randomized trial. Am J Respir Crit Care Med. 2019;199(3):313–20. https://doi.org/10.1164/rccm.201802-0286OC.CrossRefPubMedPubMedCentral

Title: Anabolism to Catabolism: Serologic Clues to Nutritional Status in Heart Failure
Authors: Laura Murphy
Alastair Gray
Emer Joyce
Publication date: 01-10-2019
Publisher: Springer US
Keywords: Sarcopenia
Underweight
Heart Failure
Malnutrition
Underweight
Biomarkers
Published in: Current Heart Failure Reports / Issue 5/2019
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-019-00437-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 5/2019

From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies

Pulmonary Hypertension in Advanced Heart Failure: Assessment and Management of the Failing RV and LV

Introduction to Topical Collection on Updates in Advanced Heart Failure

Patient Selection for Destination LVAD Therapy: Predicting Success in the Short and Long Term

Identifying Stage D Heart Failure: Data From the Most Recent Registries

Updates on Heart Transplantation

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage